Search Page

1

Cite

Share

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. Among authors: noble pw. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.

Cite

Share

2

Cite

Share

Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis.

Xie T, Wang Y, Deng N, Huang G, Taghavifar F, Geng Y, Liu N, Kulur V, Yao C, Chen P, Liu Z, Stripp B, Tang J, Liang J, Noble PW, Jiang D. Xie T, et al. Among authors: noble pw. Cell Rep. 2018 Mar 27;22(13):3625-3640. doi: 10.1016/j.celrep.2018.03.010. Cell Rep. 2018. PMID: 29590628 Free PMC article.

Cite

Share

3

Cite

Share

Pulmonary fibrosis: patterns and perpetrators.

Noble PW, Barkauskas CE, Jiang D. Noble PW, et al. J Clin Invest. 2012 Aug;122(8):2756-62. doi: 10.1172/JCI60323. Epub 2012 Aug 1. J Clin Invest. 2012. PMID: 22850886 Free PMC article. Review.

Cite

Share

4

Cite

Share

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. Among authors: noble pw. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Free article. Clinical Trial.

Cite

Share

5

Cite

Share

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Ng B, Dong J, D'Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, Xie C, Pua CJ, Chacko AM, Guimarães-Camboa N, Evans SM, Byrne AJ, Maher TM, Liang J, Jiang D, Noble PW, Schafer S, Cook SA. Ng B, et al. Among authors: noble pw. Sci Transl Med. 2019 Sep 25;11(511):eaaw1237. doi: 10.1126/scitranslmed.aaw1237. Sci Transl Med. 2019. PMID: 31554736

Cite

Share

6

Cite

Share

Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis.

Parimon T, Yao C, Stripp BR, Noble PW, Chen P. Parimon T, et al. Among authors: noble pw. Int J Mol Sci. 2020 Mar 25;21(7):2269. doi: 10.3390/ijms21072269. Int J Mol Sci. 2020. PMID: 32218238 Free PMC article. Review.

Cite

Share

7

Cite

Share

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA. Wolters PJ, et al. Among authors: noble pw. Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Lancet Respir Med. 2018. PMID: 29413083 Free PMC article. Review.

Cite

Share

8

Cite

Share

Type 2 alveolar cells are stem cells in adult lung.

Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, Hogan BL. Barkauskas CE, et al. Among authors: noble pw. J Clin Invest. 2013 Jul;123(7):3025-36. doi: 10.1172/JCI68782. Epub 2013 Jun 10. J Clin Invest. 2013. PMID: 23921127 Free PMC article.

Cite

Share

9

Cite

Share

Hyaluronan as a therapeutic target in human diseases.

Liang J, Jiang D, Noble PW. Liang J, et al. Among authors: noble pw. Adv Drug Deliv Rev. 2016 Feb 1;97:186-203. doi: 10.1016/j.addr.2015.10.017. Epub 2015 Nov 2. Adv Drug Deliv Rev. 2016. PMID: 26541745 Free PMC article. Review.

Cite

Share

10

Cite

Share

Idiopathic pulmonary fibrosis.

Meltzer EB, Noble PW. Meltzer EB, et al. Among authors: noble pw. Orphanet J Rare Dis. 2008 Mar 26;3:8. doi: 10.1186/1750-1172-3-8. Orphanet J Rare Dis. 2008. PMID: 18366757 Free PMC article. Review.

Cite

Share